Abraxis Bioscience, Inc.
http://www.abraxisbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abraxis Bioscience, Inc.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
New IO Progress For Korea's NeoImmuneTech, GI Innovation
While Chinese bioventures continue to surge ahead in immuno-oncology R&D, NeoImmuneTech says its long-acting human IL-7 in combination with pembrolizumab shows Phase IIa clinical efficacy in gastrointestinal tumors. Another Korean firm, GI Innovation, says its bispecific fusion protein/pembrolizumab combo shows synergistic effects in solid tumors at Phase I/II.
The Quality Lowdown: US FDA Warning Letters, 483 Reports Hit Poor Sterility And Lax Investigations
Bristol-Myers Squibb’s Abraxis Unit, Nephron and Lupin hit with warning letters; Lupin and Jubilant 483 inspection reports posted.
Milestone Hits Mark With RAPID Path To Potential Blockbuster Sales
The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.
Company Information
- Other Names / Subsidiaries
-
- Shimoda Biotech Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice